Pleuropulmonary disease due to pergolide use for restless legs syndrome

Chest

Volumn 120, Issue 1, 2001, Pages 313-316

  Danoff, Sonye K ^a   Grasso, Marc E ^b   Terry, Peter B ^a   Flynn, John A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Credit Suisse USA   (United States)

Author keywords

Parkinson's disease; Pergolide; Pleuropulmonary fibrosis; Restless legs syndrome

Indexed keywords

GLIPIZIDE; PERGOLIDE; WARFARIN;

AGED; ARTICLE; BRONCHOSCOPY; CASE REPORT; DERIVATIZATION; DRUG USE; DYSPNEA; EPITHELIUM CELL; FATIGUE; FEVER; HUMAN; HYDROTHORAX; INFLAMMATION; LUNG DISEASE; LUNG FIBROSIS; MALE; PHYSICAL EXAMINATION; PLEURA EFFUSION; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; THORACOCENTESIS; THORACOSCOPY; THORAX RADIOGRAPHY; TRANSBRONCHIAL BIOPSY; WEIGHT REDUCTION;

EID: 0034886358     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.120.1.313     Document Type: Article

References (8)

1. Pleuropulmonary changes induced by ergoline drugs
2. Fibrotic processes associated with long-term ergotamine therapy
3. Pergolide in the treatment of Parkinson's disease
4. A randomized controlled study of pergolide in patients with restless legs syndrome
5. Benign asbestos pleural effusion: Diagnosis and course
6. Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide
7. Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide
8. Fibrotic disorders associated with methysergide therapy for headache